Stockreport

Why Arcus Biosciences (RCUS) Is Down 15.4% After Halting Key Domvanalimab Cancer Trials And What's Next [Yahoo! Finance]

Arcus Biosciences, Inc.  (RCUS) 
Last arcus biosciences, inc. earnings: 3/5 04:10 pm Check Earnings Report
PDF and esophageal cancers, after an interim analysis found no overall survival benefit versus nivolumab plus chemotherapy, while confirming a broadly similar safety profile [Read more]